Sign in

CIK 0002035832 · <br>Emerging growth company

Aktis Oncology, Inc.

Sign in to watch
Ticker
AKTS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
852584233
Phone
978-237-4380
Business address
17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MA, 02210
  1. 4 Planned sale Chief Medical Officer sold 12,500 shares at an average $20.69 ($258,621)
  2. 4 Open-market sale Director sold 4,856 shares at $24.56 ($119,274)
  3. 4 Open-market sale Director sold 3,065 shares at $25.21 ($77,259)
  4. 4 Open-market sale Chief Operating Officer sold 50,000 shares at an average $27.75 ($1,387,558)
  5. 4 Open-market sale Chief Medical Officer sold 50,000 shares at an average $27.77 ($1,388,701)
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 3 Insider Initial Statement of Ownership
  9. 4 Open-market buy Director bought 232,870 shares at $18.00 ($4,191,660)
  10. 4 Open-market buy 10% owner bought 1,112,777 shares at $18.00 ($20,029,986)
  11. 4 Open-market buy 10% owner bought 1,112,777 shares at $18.00 ($20,029,986)
  12. 4 Open-market buy Director bought 2,222,222 shares at $18.00 ($39,999,996)
  13. 4 Open-market buy 10% owner bought 835,000 shares at $18.00 ($15,030,000)
  14. 4 Open-market buy Director bought 835,000 shares at $18.00 ($15,030,000)
  15. 4 Conversion Director acquired 19,631 shares (conversion)
  16. 3 Insider Initial Statement of Ownership
  17. 3 Insider Initial Statement of Ownership
  18. 3 Insider Initial Statement of Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 3 Insider Initial Statement of Ownership

Page 1 of 2 · 30 filings